CASTLE ROCK, Colo., April 18, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1 Test, a rapid, protein biomarker-based assay for appendicitis, today announced the appointment of Stephen A. Williams , M.D., Ph.D., Chief Medical Officer at SomaLogic, to the Company's Board of Directors. Dr. Williams brings his experience in diagnostic imaging and biomarker discovery to the Venaxis Board.
Steve Lundy , President and CEO of Venaxis, stated, "We are happy to welcome Steve to our Board and look forward to the benefit of his deep experience, both in diagnostic imaging, which is relevant to our market development and commercial strategy for the APPY1 Test, as well as in clinical biomarker validation, which will be instrumental to us in our evaluation and development of future Venaxis products."
Dr. Williams stated, "The APPY1 Test is an excellent example of how characterization of clinically relevant biomarkers can produce useful tools for addressing important diagnostic challenges. With the potential to reduce the safety risks associated with current diagnostic imaging techniques in the emergency setting, I believe there is significant clinical need and utility for the APPY1 Test. I am excited to join the Venaxis Board and to support the further development and commercialization of this, as well as potential future, biomarker-based diagnostic products."
Dr. Williams joined SomaLogic in 2009 as Chief Medical Officer. Prior to his time at SomaLogic, Dr. Williams trained as a physician at Charing Cross and Westminster Medical School, University of London, and following his internships, returned to the same institution for a Ph.D. in medicine and physiology. He s
|SOURCE Venaxis, Inc.|
Copyright©2012 PR Newswire.
All rights reserved